Showing 5,401 - 5,420 results of 106,501 for search '(( 5 ((nn decrease) OR (a decrease)) ) OR ( 50 ((we decrease) OR (mean decrease)) ))', query time: 1.05s Refine Results
  1. 5401

    Evans Blue extravasation between groups. by Guangxiao Ni (19713106)

    Published 2024
    “…MiR-199a-5p decreased the expression of PIK3R2 after MCAO, activated Akt signaling pathway, and increased the expression of Claudin-5 and VEGF in the ischemic penumbra. …”
  2. 5402
  3. 5403
  4. 5404
  5. 5405
  6. 5406
  7. 5407
  8. 5408

    Minimal data set. by Pornpan Chalermkitpanit (22110121)

    Published 2025
    “…</p><p>Methods</p><p>All 120 eligible patients diagnosed with lumbosacral radiculopathy underwent blood collection 1) before TFESI and 2) two weeks after the procedure. A 5.0 mg dexamethasone mixture with local anesthetics was injected at each epidural level. …”
  9. 5409

    Supplementary results_detailed. by Pornpan Chalermkitpanit (22110121)

    Published 2025
    “…</p><p>Methods</p><p>All 120 eligible patients diagnosed with lumbosacral radiculopathy underwent blood collection 1) before TFESI and 2) two weeks after the procedure. A 5.0 mg dexamethasone mixture with local anesthetics was injected at each epidural level. …”
  10. 5410

    Image 5_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture in mi... by Vaskar Das (21529538)

    Published 2025
    “…This study aimed at characterizing the analgesic effect of (2R,6R)-Hydroxynorketamine, an α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor dependent analgesic agent, alone or in combination with meloxicam in a murine lumbar disk puncture model.…”
  11. 5411
  12. 5412
  13. 5413
  14. 5414
  15. 5415
  16. 5416
  17. 5417
  18. 5418
  19. 5419
  20. 5420

    A PPARα Promoter Variant Impairs ERR-Dependent Transactivation and Decreases Mortality after Acute Coronary Ischemia in Patients with Diabetes by Sharon Cresci (53599)

    Published 2010
    “…Consistent with previous descriptions of PPARα in experimental models and human disease, we describe a novel <em>PPARA</em> promoter SNP that decreases transcriptional activation of <em>PPARA</em> and protects against mortality in diabetic patients after ACS.…”